|
2024
|
Invention
|
Methods of making and using extracellular domain-based chimeric proteins.
The present invention ... |
|
|
Invention
|
Fusion proteins for the treatment of cardiometabolic diseases.
The present disclosure relates to... |
|
|
Invention
|
Treatment of b cell-mediated diseases by activating cd20-targeted gamma delta t cells. The curren... |
|
|
Invention
|
Fusion proteins for the treatment of cardiometabolic diseases. The present disclosure relates to,... |
|
|
Invention
|
Tigit- and light-based chimeric proteins.
The present invention relates, inter alia, to composit... |
|
|
Invention
|
Engineered cell lines and uses thereof. The present disclosure relates, inter alia, to improved h... |
|
|
Invention
|
Methods of treating cancer with a sirp1a-based chimeric protein. The present disclosure relates, ... |
|
2023
|
Invention
|
Flt3l-based chimeric proteins.
The present invention relates, inter alia, to compositions and me... |
|
|
Invention
|
Methods of using light-based chimeric proteins. The present disclosure relates to, inter alia, co... |
|
|
Invention
|
Methods of overcoming resistance to checkpoint inhibitor therapies. The current disclosure relate... |
|
|
Invention
|
Fusion proteins for the treatment of nonalcoholic steatohepatitis. The present disclosure relates... |
|
|
Invention
|
Vsig8-based chimeric proteins.
The present invention relates, in part, to, chimeric proteins whi... |
|
|
Invention
|
Combination therapy for treatment of ovarian cancer. Combination therapies are very common in mod... |
|
|
Invention
|
Cd20-targeted gamma delta t cell modulation. The current disclosure relates to, inter alia, compo... |
|
|
Invention
|
B7h3-targeted gamma delta t cell modulation. The current disclosure relates to, inter alia, compo... |
|
|
Invention
|
Multispecific heterodimeric proteins. The current disclosure relates to, inter alia, compositions... |
|
|
Invention
|
Heterodimeric proteins and uses thereof.
The present invention relates, inter alia, to compositi... |
|
|
Invention
|
Methods of contaminant removal from protein isolates. The present invention relates, inter alia, ... |
|
2022
|
Invention
|
Sirp1a - and cd40l-based chimeric proteins. The present disclosure relates, in part, to compositi... |
|
|
Invention
|
Chimeric proteins for treating cutaneous inflammation. The present disclosure relates to, inter a... |
|
|
Invention
|
Modified mrna therapeutics. There is a need to adapt nucleic acid delivery strategies to provide ... |
|
|
Invention
|
Heterodimeric proteins for modulating gamma delta t cells. The present technology relates, inter ... |
|
|
Invention
|
Tgfbr2-based chimeric proteins.
The present invention relates, in part, to, chimeric proteins wh... |
|
|
Invention
|
Nk cell-directed chimeric proteins.
The present invention relates, inter alia, to compositions a... |
|
|
Invention
|
Methods of making and using extracellular domain-based chimeric proteins. The present invention r... |
|
|
Invention
|
Pd-1- and ox40l-based chimeric proteins. The present technology relates, inter alia, to methods o... |
|
|
Invention
|
Gamma delta t-cell costimulation.
The present disclosure relates, inter alia, to compositions an... |
|
|
Invention
|
Gamma delta t-cell costimulation. The present disclosure relates, inter alia, to compositions and... |
|
|
Invention
|
Chimeric proteins in autoimmunity. The present disclosure relates, inter alia, to compositions an... |
|
|
Invention
|
Chimeric proteins in autoimmunity. inter aliainter alia, to compositions and methods, including c... |
|
|
Invention
|
Combination therapies with sirp alpha-based chimeric proteins.
The present disclosure relates to... |
|
|
Invention
|
Combination therapies with tim-3-based chimeric proteins. The present disclosure relates to, inte... |
|
|
Invention
|
Combination therapies with sirp alpha-based chimeric proteins. inter aliainter alia, combinations... |
|
|
Invention
|
Combination therapies with sirp alpha-based chimeric proteins. The present disclosure relates to,... |
|
|
Invention
|
Mutant pd-1 extracellular domains.
The current disclosure relates to, inter alia, mutant derivat... |
|
|
Invention
|
Mutant pd-1 extracellular domains. inter alia inter alia, mutant derivatives of PD-1 protein. The... |
|
2021
|
Invention
|
Methods of treating cancer using tigit-and light-based chimeric proteins.
The present disclosure... |
|
|
Invention
|
Method of determining resistance to checkpoint inhibitor therapies.
The current disclosure relat... |
|
|
Invention
|
Methods of treating cancer using tigit-and light-based chimeric proteins. The present disclosure ... |
|
|
Invention
|
Methods of identifying gamma delta t cell-modulating agents.
The present invention relates to, i... |
|
|
Invention
|
Homodimeric and heterodimeric proteins comprising butyrophilin.
The present disclosure relates, ... |
|
2020
|
Invention
|
Chimeric proteins in autoimmunity.
The present invention relates, inter alia, to compositions an... |
|
|
Invention
|
Chimeric protein expressing t-cells.
The present invention relates to, inter alia, compositions ... |
|
|
G/S
|
Goods derived from biotechnological platform technology, namely, biotechnological pharmaceutical,... |
|
|
Invention
|
Combination therapies.
The present invention relates to, inter alia, combinations of composition... |
|
2017
|
G/S
|
Pharmaceutical preparations, namely, pharmaceutical preparations for the prevention and treatment... |
